New Treatment Regimens Used to Provide Maximum Benefit in Multiple Myeloma
Shaji K. Kumar, MD, discusses the impact of newer treatment regimens for patients with multiple myeloma and his key takeaways from the current landscape.
Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the impact of newer treatment regimens for patients with multiple myeloma and his key takeaways from the current landscape.
There’s been a lot of progress in the field of multiple myeloma, and many new agents have been introduced, but the management of these patients will need to shift to include these combination regimens.
Kumar says we want combination regimens that can provide the maximum depth of response or the best response with frontline therapy so that transplant can be used as needed, along with supportive care. In the first relapse, patients are often in good shape to tolerate highly active regimens, which helps in maximizing the impact of the first relapse therapy. The goal is to determine what regimen can be used at a given point that is likely to give the maximum benefit and the least toxicity.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
